ADC Therapeutics SA announced the first patient has been dosed in LOTIS-7, a Phase 1b clinical trial evaluating ZYNLONTA® in combination with other anti-cancer agents in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The first arm of the LOTIS-7 open-label, multi-center, multi-arm Phase 1b trial will evaluate the safety and activity of ZYNLONTA in combination with polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, high grade B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and Burkitt lymphoma. The trial will include multiple arms in two parts a dose escalation part and a dose expansion part.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.49 USD | +6.90% | -2.60% | +170.48% |
01:38pm | Guggenheim Initiates ADC Therapeutics With Buy Rating, $11 Price Target | MT |
Mar. 13 | Transcript : ADC Therapeutics SA, Q4 2023 Earnings Call, Mar 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+170.48% | 347M | |
+2.73% | 108B | |
+9.61% | 104B | |
+6.58% | 23.66B | |
-12.59% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.31% | 16.19B | |
+4.68% | 13.72B | |
+34.15% | 12.22B |
- Stock
- Equities
- Stock ADC Therapeutics SA - Nyse
- News ADC Therapeutics SA
- ADC Therapeutics SA Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents